# INO-3107 October 2026: verified outcome and blind forecast error

This is a **post-decision evaluation** and is intentionally separate from the
immutable source-frozen 2026 blind historical forecast
`BLIND-INO3107-2026-10-30-V1` at Git commit
[`6eacacd2728ac265f1b4b23571e8edb1108d5afe`](https://github.com/pdufa/pdufa-command-center/commit/6eacacd2728ac265f1b4b23571e8edb1108d5afe).
The original forecast was written November 9, 2026, **after** the FDA acted
on October 30. Consequently this case is **not** an out-of-sample prospective
prediction and does not certify forecasting skill.

## Result

- Original frozen research-only call: **CRL lean** (not calibrated).
- Actual FDA decision: **accelerated approval on October 30, 2026**.
- FDA trade name: **VOCERYQ** (previously INO-3107).
- FDA application identity: **STN BL 125825/0**.
- Indication: reducing frequency of surgical papilloma excisions in adults
  with recurrent respiratory papillomatosis.
- Correctness for this single retrospective blind research call:
  **NOT ACCURATE (0 correct / 1 decided)**.
- This result is in `data/blindHistoricalComparisons2026.json`, not in
  `data/fdaPredictionDecisionAudit.json`.

## Official outcome sources (opened only after user asked to compare)

1. FDA press announcement, dated **October 30, 2026**:
   https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis
2. FDA VOCERYQ product page and October 30 approval letter link:
   https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/voceryq
3. FDA orphan designation listing, marketing approval October 30:
   https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=751220

## Failure-mode analysis — retrospective, not prediction repair

The original CRL lean emphasized the small uncontrolled Phase 1/2 cohort,
the other RRP product already approved, and the sponsor's reported FDA
question about accelerated-approval eligibility. Those were real
predecision uncertainties, but they did **not** result in a CRL.

FDA accepted a reduction in surgical interventions as an intermediate
clinical endpoint reasonably likely to predict clinical benefit and
granted accelerated approval, conditioned on a confirmatory clinical
study. This shows that the original judgment overweighted pathway
uncertainty and underweighted the clinical importance of reducing the
surgery burden to this population.

The post-outcome FDA announcement is **not** admissible predecision
evidence, and this evaluation must never be used to revise the original
forecast or make the earlier risk appear obvious after the fact.
The SMMT November 14 prospective record is unchanged and remains pending
until its independent FDA outcome is known.
